Additional file 1: Table S1. of High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study

Multivariate analysis in APL patients with CMR. Figure S1. Consort diagram of enrolled patients in this study. Underlined patients were excluded in this study (n=25). Abbreviation: APL, acute promyelocytic leukemia; ATRA, all-trans retinoic acid; CR, complete remission, CMR, complete molecular response; WT1, Wilms tumor 1. Figure S2. Comparison of PML-RARa and WT1 expression levels between relapsed and non-relapsed patients from diagnosis to relapse or 1 year after starting maintenance for non-relapsed patients. (DOCX 152 kb

Description of studies of tuberculosis after hematopoietic stem cell transplantation published from 1990 to January 2015.

<p>Description of studies of tuberculosis after hematopoietic stem cell transplantation published from 1990 to January 2015.</p

Clinical characteristics of patients with tuberculosis after allogeneic hematopoietic stem cell transplantation.

<p>Clinical characteristics of patients with tuberculosis after allogeneic hematopoietic stem cell transplantation.</p

Overall characteristics of allogeneic hematopoietic stem cell transplantation recipients with or without tuberculosis.

<p>Overall characteristics of allogeneic hematopoietic stem cell transplantation recipients with or without tuberculosis.</p

Risk factors for tuberculosis in patients after allogeneic hematopoietic stem cell transplantation.

<p>Risk factors for tuberculosis in patients after allogeneic hematopoietic stem cell transplantation.</p

Cumulative incidence of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients with and without chronic graft-versus-host-disease.

<p>Extensive chronic GVHD was associated with the development of TB (<i>P</i> = 0.003) There is a 4.89 ± 1.32% probability of having TB disease at 1000 days after allogeneic HSCT for extensive chronic GVHD and 1.42 ± 0.50% for limited or without chronic GVHD. cGVHD, chronic graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; TB, tuberculosis.</p

Isoniazid prophylaxis and tuberculosis.

<p>INH prophylaxis did not significantly reduce the incidence of TB (<i>P</i> = 0.548). Among 5 TB patients in group B, one patient had INH prophylaxis. IGRA negative included indeterminate results. IGRA, interferon-γ release assays; INH, isoniazid; TB, tuberculosis.</p